Russ Conroy

Patients with relapsed or refractory multiple myeloma who have already undergone lymphodepletion are able to continue receiving treatment with CART-ddBCMA in the phase 2 IMMagine-1 trial.

Investigators of a retrospective study suggest that reducing myelosuppression may make chemotherapy safer and reduce the need for supportive care among those with extensive-stage small cell lung cancer.

Combining brentuximab vedotin with chemotherapy appears to significantly reduce the risk of death compared with chemotherapy alone among patients with advanced Hodgkin lymphoma.

Following safety reports of bleeding events after treatment with upifitamab rilsodotin among patients with platinum-sensitive ovarian cancer, the FDA places a partial clinical hold on enrollment for the UP-NEXT and UPGRADE-A trials.

Combining pembrolizumab with trastuzumab and chemotherapy did not raise any new safety signals among patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma in the phase 3 KEYNOTE-811 trial.

The FDA sets a Prescription Drug User Fee Act date of February 13, 2024 for NALIRIFOX as a treatment for patients with metastatic pancreatic ductal adenocarcinoma.

Approval of the Droplex EGFR Mutation Test v2 may improve access to appropriate targeted therapies for patients with EGFR-mutated non–small cell lung cancer in Korea.

Data from the phase 2 KEYNOTE-B61 trial indicate that pembrolizumab plus lenvatinib’s safety profile in the first-line treatment of patients with non-clear cell renal cell carcinoma is safe and manageable.

Investigators pause their evaluation of SC-DARIC33 in pediatric relapsed/refractory acute myeloid leukemia following a grade 5 serious adverse effect in the phase 1 PLAT-08 trial.

Inobrodib is under investigation as a treatment for patients with relapsed/refractory multiple myeloma and other hematologic malignancies in a phase 1/2a trial.

Data from the phase 3 CAPItello-291 trial support the new drug application for capivasertib plus fulvestrant as a treatment for patients with hormone receptor–positive, HER2-negative breast cancer.

The FDA’s approval of the FoundationOne Liquid CDx as a companion diagnostic may improve access to treatment with encorafenib plus cetuximab for patients with metastatic colorectal cancer harboring a BRAF V600E alteration.

A single infusion of ciltacabtagene autoleucel produces a manageable safety profile among patients with relapsed/refractory multiple myeloma in the phase 1b/2 CARTITUDE-1 study.

Findings from the phase 1b RedirecTT-1 study may support initiating larger studies evaluating teclistamab plus talquetamab for patients with relapsed or refractory multiple myeloma.

Olvimulogene nanivacirepvec virotherapy plus chemotherapy with or without bevacizumab produces a manageable safety profile in platinum-resistant or platinum-refractory ovarian cancer in the phase 2 VIRO-15 trial.

Adding blinatumomab to Interfant-06 chemotherapy appears to be feasible and safe in the treatment infants with acute lymphoblastic leukemia in a phase 2 trial.

Longitudinal ctDNA assessments may be a relevant tool for making treatment decisions for patients with EGFR-mutated non–small cell lung cancer based on findings from the phase 2 APPLE trial.

The regulatory agency has set a Prescription Drug User Fee Act date of February 7, 2024 for pembrolizumab plus chemotherapy as a treatment for patients with advanced or metastatic biliary tract cancer.

Findings from the phase 3 CARTITUDE-4 study support the supplemental biologics license application for ciltacabtagene autoleucel in the treatment of relapsed/refractory multiple myeloma.

Treatment with eftilagimod alpha in combination with pembrolizumab appears safe and well tolerated among patients with metastatic head and neck squamous cell carcinoma in the phase 2 TACTI-002 study.

Maintenance bevacizumab plus durvalumab and olaparib appears to produce a progression-free survival benefit among those with HRD-negative advanced ovarian cancer in the phase 3 DUO-O trial.

Tucatinib plus trastuzumab represents a valuable, novel option for HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer that is chemotherapy refractory, according to the authors of the phase 2 MOUNTAINEER trial.

The Molecular International Prognostic Scoring System appears to improve prognostic discrimination across all clinical end points compared with other scores in patients with myelodysplastic syndromes.

Zanubrutinib appears to produce significantly better progression-free survival and overall cardiac safety compared with ibrutinib in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

The safety review committee of the phase 1/2 Acclaim-1 trial identifies a recommended phase 2 dose of quaratusugene ozeplasmid plus osimertinib in the management of advanced non–small cell lung cancer.

Data from the phase 3 CheckMate 816 trial support the European Medicines Agency’s Committee for Medicinal Products for Human Use recommendation to approve nivolumab plus platinum-based chemotherapy as a treatment for resectable non–small cell lung cancer.

Fifteen-year follow-up data suggest the importance of considering the trade-offs between risks and benefits of active monitoring, prostatectomy, and radiotherapy for localized prostate cancer.

The FDA sets a Prescription Drug User Fee Act date of November 25, 2023 for lifileucel in the treatment of patients with advanced melanoma.

Findings from the registrational phase 1/2 TRIDENT-1 trial support the new drug application for repotrectinib in the treatment of those with ROS1-positive advanced or metastatic non–small cell lung cancer.

Data from the phase 3 DUO-E trial indicate that the safety of durvalumab/chemotherapy with or without olaparib/durvalumab or durvalumab monotherapy maintenance in recurrent endometrial cancer was consistent with previous reports of each agent.